COST AND HCRU CONSEQUENCES OF SWITCHING FROM EXISTING LONG-TERM PROPHYLAXIS TO DONIDALORSEN IN HEREDITARY ANGIOEDEMA
Author(s)
Advika Rengaraman, BSc, Will Drinkwater, BSc, MSc, Madeleine Thursfield, MA, Charlotte Heeks, BSc, MSc.
Otsuka Europe, Windsor, United Kingdom.
Otsuka Europe, Windsor, United Kingdom.
OBJECTIVES: Donidalorsen is an RNA-targeted antisense oligonucleotide (ASO) approved in the European Union, Switzerland, and United Kingdom (UK) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 years and older. Published interim data from OASISplus reported one-year outcomes in patients who switched from existing long-term prophylaxis (LTP) to donidalorsen. There is currently no evaluation of the economic impact of switching from existing LTP to donidalorsen. These analyses aimed to quantify the economic and health care resource utilisation (HCRU) impact of switching from existing LTP to donidalorsen.
METHODS: An Excel-based economic cohort model was developed to assess the economic and HCRU impact of donidalorsen versus current standard of care (SoC) over 5 years in UK patients with HAE aged 12 years and older. SoC comprised berotralstat, lanadelumab, and C1-inhibitors. The model was based on a total LTP cohort of 779 patients and excluded drug acquisition and administration costs. Hypothetical uptake assumptions were used in the model, with donidalorsen uptake assumed to increase over time from 2% in year 1 to 5%, 10%, 15%, and 25% in years 2-5, respectively, corresponding to 195 patients switching to donidalorsen by year 5. Published OASISplus switch cohort data were used to estimate HAE attack rates at baseline and after switching to donidalorsen. Cost, population, and HCRU inputs were sourced from published literature and relevant databases. HCRU outcomes included Accident and Emergency (A&E) visits, inpatient days, and consultant-led outpatient appointments.
RESULTS: Donidalorsen was estimated to deliver cumulative savings over 5 years of £4,924,901 versus SoC when accounting for attack-related costs, including on-demand therapy use and HCRU. The number of on-demand treatments avoided was 2820, corresponding to savings of £4,565,464 while HCRU were associated with savings of £359,437.
CONCLUSIONS: Switching to donidalorsen from existing LTP options may improve economic outcomes and HCRU.
METHODS: An Excel-based economic cohort model was developed to assess the economic and HCRU impact of donidalorsen versus current standard of care (SoC) over 5 years in UK patients with HAE aged 12 years and older. SoC comprised berotralstat, lanadelumab, and C1-inhibitors. The model was based on a total LTP cohort of 779 patients and excluded drug acquisition and administration costs. Hypothetical uptake assumptions were used in the model, with donidalorsen uptake assumed to increase over time from 2% in year 1 to 5%, 10%, 15%, and 25% in years 2-5, respectively, corresponding to 195 patients switching to donidalorsen by year 5. Published OASISplus switch cohort data were used to estimate HAE attack rates at baseline and after switching to donidalorsen. Cost, population, and HCRU inputs were sourced from published literature and relevant databases. HCRU outcomes included Accident and Emergency (A&E) visits, inpatient days, and consultant-led outpatient appointments.
RESULTS: Donidalorsen was estimated to deliver cumulative savings over 5 years of £4,924,901 versus SoC when accounting for attack-related costs, including on-demand therapy use and HCRU. The number of on-demand treatments avoided was 2820, corresponding to savings of £4,565,464 while HCRU were associated with savings of £359,437.
CONCLUSIONS: Switching to donidalorsen from existing LTP options may improve economic outcomes and HCRU.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE724
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Rare & Orphan Diseases